28
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Daclizumab in anaplastic large cell lymphoma

Page 175 | Received 25 Jun 2005, Published online: 01 Jul 2009

References

  • Linden O. Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab. New England Journal of Medicine 2004; 351: 1466–1467
  • Koller C A, Kantarjian H M, Thomas D, O'Brien S, Rios M B, Kornblau S, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997; 11: 2039–2044
  • Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, et al. Short-pulse B-non Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM90. Blood 2001; 97: 3699–3706
  • Janik J E, Morris J C, Pittaluga S, McDonald K, Raffeld M, Jaffe E S, et al. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 2004; 104: 3355–3357

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.